# Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

> **NCT07344948** · EARLY_PHASE1 · RECRUITING · sponsor: **Neurosterix** · enrollment: 73 (estimated)

## Conditions studied

- Healthy Participants
- Schizophrenia Diagnosis

## Interventions

- **DRUG:** NTX-253
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07344948
- **Lead sponsor:** Neurosterix
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-03
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344948, "Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07344948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*